Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-27T07:32:56.475Z Has data issue: false hasContentIssue false
  • English
  • Français

The value of cognitive behavioral therapy on quality of life in addition to pharmacotherapy in adults with ADHD

Published online by Cambridge University Press:  01 September 2022

R. Wettstein ,
Y. Klabbers ,
E. Romijn ,
J. Nieuwveen ,
H. Kroesen ,
K. Wettstein  and
G. Dumont
R. Wettstein*
Affiliation:
Amsterdam university medical center, Clinical Pharmacology And Pharmacy, Amsterdam, Netherlands ADHDcentraal, Research & Development, Nieuwegein, Netherlands
Y. Klabbers
Affiliation:
GGNet, Ivb, Warnsveld, Netherlands
E. Romijn
Affiliation:
ADHDcentraal, Research & Development, Nieuwegein, Netherlands
J. Nieuwveen
Affiliation:
ADHDcentraal, Research & Development, Nieuwegein, Netherlands
H. Kroesen
Affiliation:
ADHDcentraal, Research & Development, Nieuwegein, Netherlands
K. Wettstein
Affiliation:
ADHDcentraal, Research & Development, Nieuwegein, Netherlands
G. Dumont
Affiliation:
Amsterdam university medical center, Clinical Pharmacology And Pharmacy, Amsterdam, Netherlands ADHDcentraal, Research & Development, Nieuwegein, Netherlands
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Treatment options for ADHD in adults consist of psycho-education, cognitive behavioral therapy (CBT), pharmacotherapy or a combination thereof. Current studies do not yet provide insights into the additive effects of CBT and pharmacotherapy regarding the quality of life in adults with ADHD.

Objectives

In this study, we investigated the effect of CBT combined with pharmacotherapy on the quality of life in adults with ADHD compared to pharmacotherapy alone.

Methods

In this multicenter prospective cohort study a total of 627 patients were included, 305 where included in the pharmacotherapy only group and 322 in de combination group (CBT and pharmacotherapy). The Adult ADHD Quality-of-Life scale (AAQoL) was conducted at baseline and at the end of treatment.

Results

No significant differences were found in gender or age between groups at baseline. The average improvement in the AAQoL total score in the pharmacotherapy group was 26.81(17.12) and in the combination group 25.45(16.33) and showed no significant difference (t(543) = 0.96, p = 0.34). At baseline the average total score in the pharmacotherapy group was 45.5(12.37) and 42.22(12.73) in the combination group (t(543)=2.86, p = 0.004). The average total score at the end of treatment in the pharmacotherapy and combination group was 72.31(12.99) and 67.67(12.45), respectively (t(543)=426, p <0.001).

Conclusions

To our knowledge, this is the first study to describe the value of CBT in addition to pharmacotherapy on the quality of life in adults with ADHD. Contrary to our expectations, there was no significant effect of CBT in addition to pharmacotherapy on the quality of life.

Disclosure

No significant relationships.

Keywords

Cognitive behavioral therapyQuality of Lifeadultsadhd
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S610 - S611
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.